Semin Thromb Hemost 2013; 39(08): 913-927
DOI: 10.1055/s-0033-1357504
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Cerebral Venous Thrombosis and Thrombophilia: A Systematic Review and Meta-Analysis

Mandy N. Lauw
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
2   Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
*   Mandy N. Lauw and Stefano Barco have contributed equally to this study
,
Stefano Barco
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
3   Department of Internal Medicine, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
*   Mandy N. Lauw and Stefano Barco have contributed equally to this study
,
Jonathan M. Coutinho
4   Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands
,
Saskia Middeldorp
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
15 October 2013 (online)

Abstract

Cerebral venous thrombosis (CVT) is a rare manifestation of venous thromboembolism (VTE) and stroke. The aim of our systematic review was to provide an updated summary of the strength of association between CVT and thrombophilia and to explore the relevance of thrombophilia for recurrence of CVT or other VTE, or other outcome variables. MEDLINE (via PubMed), EMBASE (via Ovid), and CENTRAL were systematically searched, including references of retrieved articles. Cohort studies of ≥ 40 patients and case-control studies comparing the prevalence of thrombophilia in patients with CVT and unrelated controls were eligible. Two reviewers independently selected studies, assessed quality, and extracted data. A meta-analysis was performed for high quality case-control studies with unselected cases and healthy controls. Odds ratios with 95% confidence intervals were calculated and pooled. We included 23 cohort studies and 33 case-control studies. A significant association was demonstrated between CVT and all inherited thrombophilic factors, as well as increased levels of homocysteine. Inconclusive results were found on the relevance of thrombophilia for recurrent CVT or other VTE. Although there is a strong association between CVT and thrombophilia, the clinical relevance of thrombophilia testing in patients with CVT seems limited, similarly to other forms of VTE.

 
  • References

  • 1 Einhäupl K, Stam J, Bousser MG , et al; European Federation of Neurological Societies. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010; 17 (10) 1229-1235
  • 2 Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352 (17) 1791-1798
  • 3 Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6 (2) 162-170
  • 4 Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke 2012; 43 (12) 3375-3377
  • 5 Coutinho JM, Ferro JM, Canhão P , et al. Cerebral venous and sinus thrombosis in women. Stroke 2009; 40 (7) 2356-2361
  • 6 Cantú C, Barinagarrementeria F. Cerebral venous thrombosis associated with pregnancy and puerperium. Review of 67 cases. Stroke 1993; 24 (12) 1880-1884
  • 7 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160 (6) 809-815
  • 8 Vossen CY, Conard J, Fontcuberta J , et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004; 2 (9) 1526-1532
  • 9 Coppens M, Reijnders JH, Middeldorp S, Doggen CJ, Rosendaal FR. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost 2008; 6 (9) 1474-1477
  • 10 Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293 (19) 2352-2361
  • 11 Bates SM, Greer IA, Middeldorp S , et al; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl) e691S-e736S
  • 12 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25 (9) 603-605
  • 13 Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007; 36 (3) 666-676
  • 14 Wells GA, Shea B, O'Connell D , et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed March 3, 2013
  • 15 deVeber G, Andrew M, Adams C , et al; Canadian Pediatric Ischemic Stroke Study Group. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345 (6) 417-423
  • 16 Camargo EC, Massaro AR, Bacheschi LA , et al. Ethnic differences in cerebral venous thrombosis. Cerebrovasc Dis 2005; 19 (3) 147-151
  • 17 Terazzi E, Mittino D, Rudà R , et al; Cerebral Venous Thrombosis Group. Cerebral venous thrombosis: a retrospective multicentre study of 48 patients. Neurol Sci 2005; 25 (6) 311-315
  • 18 Wasay M, Bakshi R, Bobustuc G , et al. Cerebral venous thrombosis: analysis of a multicenter cohort from the United States. J Stroke Cerebrovasc Dis 2008; 17 (2) 49-54
  • 19 Coutinho JM, Ferro JM, Canhão P , et al. Cerebral venous and sinus thrombosis in women. Stroke 2009; 40 (7) 2356-2361
  • 20 Algahtani HA, Abdu AP, Shami AM , et al. Cerebral venous sinus thrombosis in Saudi Arabia. Neurosciences (Riyadh) 2011; 16 (4) 329-334
  • 21 Dentali F, Poli D, Scoditti U , et al; CErebral VEin Thrombosis International Study Investigators. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012; 10 (7) 1297-1302
  • 22 Narayan D, Kaul S, Ravishankar K , et al. Risk factors, clinical profile, and long-term outcome of 428 patients of cerebral sinus venous thrombosis: insights from Nizam's Institute Venous Stroke Registry, Hyderabad (India). Neurol India 2012; 60 (2) 154-159
  • 23 Uzar E, Ekici F, Acar A , et al. Cerebral venous sinus thrombosis: an analyses of 47 patients. Eur Rev Med Pharmacol Sci 2012; 16 (11) 1499-1505
  • 24 Deschiens MA, Conard J, Horellou MH , et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996; 27 (10) 1724-1730
  • 25 de Bruijn SF, de Haan RJ, Stam J ; For The Cerebral Venous Sinus Thrombosis Study Group. Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. J Neurol Neurosurg Psychiatry 2001; 70 (1) 105-108
  • 26 Breteau G, Mounier-Vehier F, Godefroy O , et al. Cerebral venous thrombosis 3-year clinical outcome in 55 consecutive patients. J Neurol 2003; 250 (1) 29-35
  • 27 Amberger N, Masuhr F, Valdueza JM, Vetter B, Weih M. A negative personal and family history for venous thrombotic events is not sufficient to exclude thrombophilia in patients with cerebral venous thrombosis. Eur J Neurol 2004; 11 (8) 555-558
  • 28 Stolz E, Rahimi A, Gerriets T, Kraus J, Kaps M. Cerebral venous thrombosis: an all or nothing disease? Prognostic factors and long-term outcome. Clin Neurol Neurosurg 2005; 107 (2) 99-107
  • 29 De Stefano V, Fiorini A, Rossi E , et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5 (4) 708-714
  • 30 Bellucci S, Cassinat B, Bonnin N, Marzac C, Crassard I. The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thromb Haemost 2008; 99 (6) 1119-1120
  • 31 Zubkov AY, McBane RD, Brown RD, Rabinstein AA. Brain lesions in cerebral venous sinus thrombosis. Stroke 2009; 40 (4) 1509-1511
  • 32 Alonso-Cánovas A, Masjuan J, González-Valcárcel J , et al. [Cerebral venous thrombosis: when etiology makes the difference]. Neurologia 2009; 24 (7) 439-445
  • 33 Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 2010; 121 (25) 2740-2746
  • 34 Aaron S, Alexander M, Maya T , et al. Underlying prothrombotic states in pregnancy associated cerebral venous thrombosis. Neurol India 2010; 58 (4) 555-559
  • 35 Yokus O, Sahin Balcik O, Albayrak M , et al. Evaluation of risk factors for thrombophilia in patients with cerebral venous thrombosis. Turk J Hematol 2010; 27: 162-167
  • 36 Sanz Gallego I, Fuentes B, Martínez-Sánchez P, Díez Tejedor E. Do cerebral venous thrombosis risk factors influence the development of an associated venous infarction?. Neurologia 2011; 26 (1) 13-19
  • 37 Passamonti SM, Biguzzi E, Cazzola M , et al. The JAK2 V617F mutation in patients with cerebral venous thrombosis. J Thromb Haemost 2012; 10 (6) 998-1003
  • 38 Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996; 75 (3) 393-394
  • 39 Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996; 27 (10) 1721-1723
  • 40 Lüdemann P, Nabavi DG, Junker R , et al. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients. Stroke 1998; 29 (12) 2507-2510
  • 41 Hillier CE, Collins PW, Bowen DJ, Bowley S, Wiles CM. Inherited prothrombotic risk factors and cerebral venous thrombosis. QJM 1998; 91 (10) 677-680
  • 42 Weih M, Vetter B, Ziemer S , et al. Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis. J Neurol 1998; 245 (3) 149-152
  • 43 Christopher R, Nagaraja D, Dixit NS, Narayanan CP. Anticardiolipin antibodies: a study in cerebral venous thrombosis. Acta Neurol Scand 1999; 99 (2) 121-124
  • 44 Madonna P, De Stefano V, Coppola A, Albisinni R, Cerbone AM. G20210A PRTH gene mutation and other trombophilic polymorphisms in patients with cerebral vein thrombosis. Stroke 2000; 31 (7) 1787-1788
  • 45 Voetsch B, Damasceno BP, Camargo EC , et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000; 83 (2) 229-233
  • 46 Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 2002; 70 (2) 126-132
  • 47 Bonduel M, Sciuccati G, Hepner M , et al. Factor V Leiden and prothrombin gene G20210A mutation in children with cerebral thromboembolism. Am J Hematol 2003; 73 (2) 81-86
  • 48 Heller C, Heinecke A, Junker R , et al; Childhood Stroke Study Group. Cerebral venous thrombosis in children: a multifactorial origin. Circulation 2003; 108 (11) 1362-1367
  • 49 Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood 2003; 102 (4) 1363-1366
  • 50 Boncoraglio G, Carriero MR, Chiapparini L , et al. Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis. Eur J Neurol 2004; 11 (6) 405-409
  • 51 Cantu C, Alonso E, Jara A , et al. Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis. Stroke 2004; 35 (8) 1790-1794
  • 52 Ventura P, Cobelli M, Marietta M, Panini R, Rosa MC, Salvioli G. Hyperhomocysteinemia and other newly recognized inherited coagulation disorders (factor V Leiden and prothrombin gene mutation) in patients with idiopathic cerebral vein thrombosis. Cerebrovasc Dis 2004; 17 (2-3) 153-159
  • 53 Tufano A, Coppola A, Varricchione N , et al. Predisposing factors in patients with early-onset cerebral vein thrombosis. Thromb Res 2005; 115 (5) 439-440
  • 54 Kenet G, Waldman D, Lubetsky A , et al. Paediatric cerebral sinus vein thrombosis. A multi-center, case-controlled study. Thromb Haemost 2004; 92 (4) 713-718
  • 55 Rodrigues CA, Rocha LK, Morelli VM, Franco RF, Lourenço DM. Prothrombin G20210A mutation, and not factor V Leiden mutation, is a risk factor for cerebral venous thrombosis in Brazilian patients. J Thromb Haemost 2004; 2 (7) 1211-1212
  • 56 Le Cam-Duchez V, Bagan-Triquenot A, Ménard JF, Mihout B, Borg JY. Association of the protein C promoter CG haplotype and the factor II G20210A mutation is a risk factor for cerebral venous thrombosis. Blood Coagul Fibrinolysis 2005; 16 (7) 495-500
  • 57 Gadelha T, André C, Jucá AA, Nucci M. Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis 2005; 19 (1) 49-52
  • 58 Dindagur N, Kruthika-Vinod TP, Christopher R. Thrombophilic gene polymorphisms in puerperal cerebral veno-sinus thrombosis. J Neurol Sci 2006; 249 (1) 25-30
  • 59 Lichy C, Dong-Si T, Reuner K , et al. Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems. J Neurol 2006; 253 (3) 316-320
  • 60 Bugnicourt JM, Roussel B, Tramier B, Lamy C, Godefroy O. Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control study. J Neurol Neurosurg Psychiatry 2007; 78 (7) 699-701
  • 61 Colaizzo D, Amitrano L, Iannaccone L , et al. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 2007; 44 (6) 412-416
  • 62 Stolz E, Valdueza JM, Grebe M , et al. Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study. J Neurol 2007; 254 (6) 729-734
  • 63 Cesarman-Maus G, Cantú-Brito C, Barinagarrementeria F , et al. Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke 2011; 42 (2) 501-503
  • 64 Laugesaar R, Kahre T, Kolk A, Uustalu U, Kool P, Talvik T. Factor V Leiden and prothrombin 20210G>A [corrected] mutation and paediatric ischaemic stroke: a case-control study and two meta-analyses. Acta Paediatr 2010; 99 (8) 1168-1174
  • 65 Rahimi Z, Mozafari H, Bigvand AH , et al. Cerebral venous and sinus thrombosis and thrombophilic mutations in Western Iran: association with factor V Leiden. Clin Appl Thromb Hemost 2010; 16 (4) 430-434
  • 66 Ringelstein M, Jung A, Berger K , et al. Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults. J Neurol 2012; 259 (11) 2287-2292
  • 67 Ashjazadeh N, Poursadeghfard M, Farjadian S. Factor V G1691A and prothrombin G20210A gene polymorphisms among Iranian patients with cerebral venous thrombosis. . Neurol Asia 2012; 17 (3) 199-203
  • 68 Ben Salem-Berrabah O, Fekih-Mrissa N, N'siri B , et al. Thrombophilic polymorphisms - factor V Leiden G1691A, prothrombin G20210A and MTHFR C677T - in Tunisian patients with cerebral venous thrombosis. J Clin Neurosci 2012; 19 (9) 1326-1327
  • 69 Libourel EJ, ten Kate MK, Brouwer JL, Veeger NJ, van der Meer J. Contribution of multiple thrombophilic and transient risk factors in the development of cerebral venous thrombosis. Thromb Res 2007; 121 (3) 301-307
  • 70 Wysokinska EM, Wysokinski WE, Brown RD , et al. Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis. Neurology 2008; 70 (8) 627-633
  • 71 Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338 (25) 1793-1797
  • 72 Girot M, Ferro JM, Canhão P , et al; ISCVT Investigators. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke 2007; 38 (2) 337-342
  • 73 Gosk-Bierska I, Wysokinski W, Brown Jr RD , et al. Cerebral venous sinus thrombosis: Incidence of venous thrombosis recurrence and survival. Neurology 2006; 67 (5) 814-819
  • 74 Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood 2006; 107 (7) 2766-2773
  • 75 Kenet G, Lütkhoff LK, Albisetti M , et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 2010; 121 (16) 1838-1847
  • 76 Dayan N, Holcroft CA, Tagalakis V. The risk of venous thrombosis, including cerebral vein thrombosis, among women with thrombophilia and oral contraceptive use: a meta-analysis. Clin Appl Thromb Hemost 2011; 17 (6) E141-E152
  • 77 Marjot T, Yadav S, Hasan N, Bentley P, Sharma P. Genes associated with adult cerebral venous thrombosis. Stroke 2011; 42 (4) 913-918
  • 78 Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160 (1) 49-52
  • 79 de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP ; The Cerebral Venous Sinus Thrombosis Study Group Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. BMJ 1998; 316 (7131) 589-592
  • 80 Cohn DM, Vansenne F, de Borgie CA, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev 2012; 12: CD007069
  • 81 Junker R, Nabavi DG, Wolff E , et al. Plasminogen activator inhibitor-1 4G/4G-genotype is associated with cerebral sinus thrombosis in factor V Leiden carriers. Thromb Haemost 1998; 80 (4) 706-707